NCT04162639

Brief Summary

The purpose of this research study is to look at how the body's immune system reacts to temporary skin grafts from deceased donors.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2021

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 11, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 14, 2019

Completed
1.2 years until next milestone

Study Start

First participant enrolled

February 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2023

Completed
Last Updated

March 19, 2021

Status Verified

March 1, 2021

Enrollment Period

2 years

First QC Date

November 11, 2019

Last Update Submit

March 16, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in participant's panel reactive antibody (PRA) score at 1 month

    Standard PRA assays will be performed on blood samples drawn from participants giving a percent score representing the number of reactions in the sample.

    Baseline to 1 month

  • Change in participant's panel reactive antibody (PRA) score at 6 months

    Standard PRA assays will be performed on blood samples drawn from participants giving a percent score representing the number of reactions in the sample.

    Baseline to 6 months

  • Change in participant's panel reactive antibody (PRA) score at 12 month

    Standard PRA assays will be performed on blood samples drawn from participants giving a percent score representing the number of reactions in the sample.

    Baseline to 12 months

Study Arms (4)

One donor

EXPERIMENTAL

Participants will receive skin allograft from 1 distinct cadavers.

Biological: Skin allograft

Two donors

EXPERIMENTAL

Participants will receive skin allograft from 2 distinct cadavers.

Biological: Skin allograft

Three donors

EXPERIMENTAL

Participants will receive skin allograft from 3 distinct cadavers.

Biological: Skin allograft

Control

NO INTERVENTION

Participants will be burned patients with wounds that do not require skin allografts, but are instead reconstructed with their own skin (skin autografts) in a single stage.

Interventions

Skin allograftBIOLOGICAL

Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.

One donorThree donorsTwo donors

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18 years or older
  • Burns of deep partial thickness or full thickness depth totaling less than or equal to 10% total body surface area.
  • Injury requiring staged reconstruction with allograft skin (experimental group)
  • Injury requiring reconstruction with autograft skin (i.e. no cadaver skin; control group)

You may not qualify if:

  • Burns exceeding 10% total body surface area.
  • Pre-existing allosensitization at time of injury
  • Blood or blood product transfusion requirement
  • Pregnancy at the time of injury or during study period
  • History of solid organ transplant during study period
  • History of autoimmune disorder (systemic lupus erythematosus, etc.)
  • History of mechanical circulatory support (extracorporeal membrane oxygenation, ventricular assist device, total artificial heart) during study period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Duhamel P, Suberbielle C, Grimbert P, Leclerc T, Jacquelinet C, Audry B, Bargues L, Charron D, Bey E, Lantieri L, Hivelin M. Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation. Transpl Int. 2015 May;28(5):582-93. doi: 10.1111/tri.12540. Epub 2015 Feb 26.

    PMID: 25683513BACKGROUND
  • Klein HJ, Lehner F, Schweizer R, Rusi-Elsener B, Nilsson J, Plock JA. Screening of HLA sensitization during acute burn care. Burns. 2018 Aug;44(5):1330-1335. doi: 10.1016/j.burns.2018.01.010. Epub 2018 Mar 7.

    PMID: 29929900BACKGROUND
  • Klein HJ, Schanz U, Hivelin M, Waldner M, Koljonen V, Guggenheim M, Giovanoli P, Gorantla VS, Fehr T, Plock JA. Sensitization and desensitization of burn patients as potential candidates for vascularized composite allotransplantation. Burns. 2016 Mar;42(2):246-57. doi: 10.1016/j.burns.2015.05.019. Epub 2015 Sep 29.

    PMID: 26392022BACKGROUND

MeSH Terms

Conditions

Burns

Condition Hierarchy (Ancestors)

Wounds and Injuries

Study Officials

  • Michael Feldman

    Virginia Commonwealth University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 11, 2019

First Posted

November 14, 2019

Study Start

February 1, 2021

Primary Completion

February 1, 2023

Study Completion

February 1, 2023

Last Updated

March 19, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share